PML (promyelocytic leukemia protein) is a TRIM19 E3 SUMO-protein ligase that organizes PML nuclear bodies (NBs), membrane-less organelles crucial for antiviral defense and cellular homeostasis 1. PML exhibits broad antiviral activity through isoform-specific mechanisms: PML-4 restricts varicella zoster virus via capsid sequestration; PML-3 induces apoptosis against poliovirus through p53 recruitment; and PML-6 restricts cytomegalovirus and influenza [UniProt]. Isoforms PML-3 and PML-6 display highest SUMO-ligase activity [UniProt]. PML NBs function as nuclear depot centers regulating interferon-stimulated gene transcription and histone dynamics through HIRA recruitment via SUMO-SIM interactions 2. During cellular senescence, PML NBs coordinate with HIRA and p62/SQSTM1 to regulate the senescence-associated secretory phenotype through cGAS/STING-NF-κB signaling 3. PML undergoes TGF-β-induced SUMOylation and nuclear matrix translocation to promote caspase-8 activation and apoptosis 1. Clinically, PML-RARA fusion drives acute promyelocytic leukemia, which responds to arsenic-induced SUMO/ubiquitin-dependent degradation via TOPORS and RNF4 pathways 45. PML protein levels modulate viral protein interactions and immune responses 6.